Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
reMYND - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'reMYND - Product Pipeline Review - 2014', provides an overview of the reMYND's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of reMYND's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of reMYND including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of reMYND's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the reMYND's pipeline products Reasons to buy - Evaluate reMYND's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of reMYND in its therapy areas of focus - Identify new drug targets and therapeutic classes in the reMYND's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of reMYND and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of reMYND - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of reMYND and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 reMYND Snapshot 5 reMYND Overview 5 Key Information 5 Key Facts 5 reMYND - Research and Development Overview 6 Key Therapeutic Areas 6 reMYND - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 reMYND - Pipeline Products Glance 10 reMYND - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 reMYND - Drug Profiles 12 ReS13-I Program 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 ReS19-T Program 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 ReS3-T Program 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ReS39-I Program 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 ReS9-S Program 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ReS10-T Program 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ReS12-S Program 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ReS8-T Program 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecules for Amyotrophic Lateral Sclerosis 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecules to Inhibit Huntingtin for Huntington's Disease 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 reMYND - Pipeline Analysis 22 reMYND - Pipeline Products by Target 22 reMYND - Pipeline Products by Molecule Type 23 reMYND - Pipeline Products by Mechanism of Action 24 reMYND - Locations And Subsidiaries 25 Head Office 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables reMYND, Key Information 5 reMYND, Key Facts 5 reMYND - Pipeline by Indication, 2014 7 reMYND - Pipeline by Stage of Development, 2014 8 reMYND - Monotherapy Products in Pipeline, 2014 9 reMYND - Preclinical, 2014 10 reMYND - Discovery, 2014 11 reMYND - Pipeline by Target, 2014 22 reMYND - Pipeline by Molecule Type, 2014 23 reMYND - Pipeline Products by Mechanism of Action, 2014 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.